Interestingly, in the present study, we found a simultaneous 1.5-, 1.6-, 1.7-, 2.0-, and 2.6-fold increase in SPT16, AURKA, C-MYC, N-MYC, and AURKB gene expression in primary AML patients carrying a high (>0.5) FLT3-ITD mutation allelic load compared with low (<0.5) FLT3-ITD allelic load carriers. This evidence concerns the gene MYC and acute myeloid leukemia.